Knocking Down


Journal

Cells
ISSN: 2073-4409
Titre abrégé: Cells
Pays: Switzerland
ID NLM: 101600052

Informations de publication

Date de publication:
10 03 2023
Historique:
received: 31 01 2023
revised: 01 03 2023
accepted: 03 03 2023
medline: 30 3 2023
entrez: 29 3 2023
pubmed: 30 3 2023
Statut: epublish

Résumé

Human induced pluripotent stem cells (hiPSCs) have the potential to be differentiated into any cell type, making them a relevant tool for therapeutic purposes such as cell-based therapies. In particular, they show great promise for obesity treatment as they represent an unlimited source of brown/beige adipose progenitors (hiPSC-BAPs). However, the low brown/beige adipocyte differentiation potential in 2D cultures represents a strong limitation for clinical use. In adipose tissue, besides its cell cycle regulator functions, the cyclin-dependent kinase inhibitor 2A (

Identifiants

pubmed: 36980212
pii: cells12060870
doi: 10.3390/cells12060870
pmc: PMC10047013
pii:
doi:

Substances chimiques

CDKN2A protein, human 0
Cyclin-Dependent Kinase Inhibitor p16 0
Cyclin-Dependent Kinase Inhibitor Proteins 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Références

Biomolecules. 2020 Sep 22;10(9):
pubmed: 32971832
Biochem Biophys Res Commun. 2014 Apr 18;446(4):1126-31
pubmed: 24680834
Obes Rev. 2018 Feb;19(2):121-149
pubmed: 29144594
Cell. 2012 Jul 20;150(2):366-76
pubmed: 22796012
Nutr Metab (Lond). 2022 Sep 6;19(1):61
pubmed: 36068578
Stem Cells Int. 2017;2017:2767916
pubmed: 29158739
Sci Rep. 2019 Apr 16;9(1):6165
pubmed: 30992469
PLoS One. 2012;7(9):e46483
pubmed: 23029528
Trends Endocrinol Metab. 2015 Apr;26(4):176-84
pubmed: 25744911
Front Endocrinol (Lausanne). 2020 Dec 23;11:572089
pubmed: 33424765
Int J Mol Sci. 2019 Feb 11;20(3):
pubmed: 30754657
Stem Cells. 2017 Jul;35(7):1799-1814
pubmed: 28470788
Front Mol Biosci. 2020 May 08;7:76
pubmed: 32457917
Nat Genet. 2012 Sep;44(9):981-90
pubmed: 22885922
J Biol Chem. 2003 Apr 4;278(14):11888-96
pubmed: 12529376
Dev Cell. 2021 Apr 5;56(7):985-999.e4
pubmed: 33711247
Cell Metab. 2017 Jan 10;25(1):166-181
pubmed: 27889388
J Endocrinol. 2019 May 10;241(3):R97-R109
pubmed: 31144796
Exp Cell Res. 2005 Feb 1;303(1):138-47
pubmed: 15572034
Genes Dev. 2017 Jan 15;31(2):127-140
pubmed: 28202540
Sci Rep. 2021 Apr 14;11(1):8177
pubmed: 33854178
Int J Mol Sci. 2020 Jun 16;21(12):
pubmed: 32560163
Adv Sci (Weinh). 2021 Aug;8(16):e2100106
pubmed: 34165908
Nat Med. 2015 Aug;21(8):863-5
pubmed: 26147760
Front Med. 2019 Jun;13(3):314-329
pubmed: 30066061
Nat Commun. 2016 Mar 09;7:10895
pubmed: 26955961
J Clin Invest. 2012 Mar;122(3):1022-36
pubmed: 22307324
Sci Rep. 2016 Aug 31;6:32490
pubmed: 27577850
Cell Metab. 2015 Oct 6;22(4):546-59
pubmed: 26445512
Mol Metab. 2018 Feb;8:65-76
pubmed: 29237539
Mol Cell Biol. 2008 Jun;28(11):3804-16
pubmed: 18391018
Cell Rep. 2018 Dec 11;25(11):3215-3228.e9
pubmed: 30540952
Endocr Rev. 2002 Feb;23(1):38-89
pubmed: 11844744
Cell Metab. 2017 May 2;25(5):1027-1036
pubmed: 28467922
Cells. 2021 May 06;10(5):
pubmed: 34066631
Mol Cell Biol. 1996 Aug;16(8):4128-36
pubmed: 8754811
Front Endocrinol (Lausanne). 2020 Jan 21;10:932
pubmed: 32038489
J Endocrinol. 2007 Jun;193(3):435-44
pubmed: 17535881
Mol Aspects Med. 2019 Aug;68:74-81
pubmed: 31228478
Trends Endocrinol Metab. 2011 Aug;22(8):333-43
pubmed: 21646028
Trends Endocrinol Metab. 2014 Jun;25(6):293-302
pubmed: 24793638
Stem Cells. 2014 Jun;32(6):1459-67
pubmed: 24302443
Curr Opin Lipidol. 2016 Feb;27(1):19-25
pubmed: 26655292
Endocr Rev. 2017 Feb 1;38(1):46-68
pubmed: 27849358
Cell Metab. 2012 Sep 5;16(3):394-406
pubmed: 22958922
Nat Cell Biol. 2013 Mar;15(3):302-8
pubmed: 23434825
Endocrinology. 2018 May 1;159(5):2036-2049
pubmed: 29596616
Lipids. 2011 Nov;46(11):1033-42
pubmed: 21894465
Methods Mol Biol. 2022;2454:495-507
pubmed: 33982274
Nat Med. 2013 May;19(5):557-66
pubmed: 23652116
J Endocrinol. 2016 Jul;230(1):1-11
pubmed: 27106108
J Biol Chem. 1999 Apr 30;274(18):12632-41
pubmed: 10212243

Auteurs

Yasmina Kahoul (Y)

Univ. Lille, INSERM, CNRS, CHU Lille, Institut Pasteur de Lille, U1283-UMR8199-EGID, F-59000 Lille, France.

Xi Yao (X)

Faculté de Médecine, CNRS, INSERM, iBV, Université Côte d'Azur, CEDEX 2, F-06107 Nice, France.

Frédérik Oger (F)

Univ. Lille, INSERM, CNRS, CHU Lille, Institut Pasteur de Lille, U1283-UMR8199-EGID, F-59000 Lille, France.

Maeva Moreno (M)

Univ. Lille, INSERM, CNRS, CHU Lille, Institut Pasteur de Lille, U1283-UMR8199-EGID, F-59000 Lille, France.

Souhila Amanzougarene (S)

Univ. Lille, INSERM, CNRS, CHU Lille, Institut Pasteur de Lille, U1283-UMR8199-EGID, F-59000 Lille, France.

Mehdi Derhourhi (M)

Univ. Lille, INSERM, CNRS, CHU Lille, Institut Pasteur de Lille, U1283-UMR8199-EGID, F-59000 Lille, France.

Emmanuelle Durand (E)

Univ. Lille, INSERM, CNRS, CHU Lille, Institut Pasteur de Lille, U1283-UMR8199-EGID, F-59000 Lille, France.

Raphael Boutry (R)

Univ. Lille, INSERM, CNRS, CHU Lille, Institut Pasteur de Lille, U1283-UMR8199-EGID, F-59000 Lille, France.

Amélie Bonnefond (A)

Univ. Lille, INSERM, CNRS, CHU Lille, Institut Pasteur de Lille, U1283-UMR8199-EGID, F-59000 Lille, France.
Department of Metabolism, Imperial College London, London SW7 2BX, UK.

Philippe Froguel (P)

Univ. Lille, INSERM, CNRS, CHU Lille, Institut Pasteur de Lille, U1283-UMR8199-EGID, F-59000 Lille, France.
Department of Metabolism, Imperial College London, London SW7 2BX, UK.

Christian Dani (C)

Faculté de Médecine, CNRS, INSERM, iBV, Université Côte d'Azur, CEDEX 2, F-06107 Nice, France.

Jean-Sébastien Annicotte (JS)

Univ. Lille, Inserm, CHU Lille, Institut Pasteur Lille, U1167 - RID-AGE - Facteurs de Risque et Déterminants Moléculaires des Maladies liées au Vieillissement, F-59000 Lille, France.

Christophe Breton (C)

Univ. Lille, INSERM, CNRS, CHU Lille, Institut Pasteur de Lille, U1283-UMR8199-EGID, F-59000 Lille, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH